A Phase 4 interventional study of To maintain anticoagulant therapy during the polypectomy of colorectal lesions in Anticoagulated Patients, sponsored by Outcomes'10. Active, not recruiting at 10 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Outcomes'10 · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Hemorrhage with a site in Spain — 10 open to participants now, 15 under way, 5 of them phase 3. Hemorrhage · Spain.
Among the 53 studies in Hemorrhage with a site in Spain, this one is the 13th largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 4, reaches primary completion later than 4 of the 14 other live ones, and was the 51st registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →10 of the 53 studies in Hemorrhage with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, Ireland, Latvia and 2 more countries
Ages 18+
Takeda · Sites in Spain, United States, Australia and 12 more countries
Ages 18+
Instituto de Investigación Marqués de Valdecilla · Sites in Spain
Ages 18–65
Takeda · Sites in Spain, United States, Australia and 15 more countries
Ages 18+
Pfizer · Sites in Spain, United States, Australia and 11 more countries
Ages 18+ · Men only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 481 is above the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 188 across the 39 interventional studies, 407 across the 14 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 53 have an industry lead sponsor. The 10 most frequent:
Outcomes'10 is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Outcomes'10 has 1 study filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Hemorrhage with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283356Fundacin Biomedica Galicia SurSingle Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Hemorrhage with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to find out if it is safe to keep taking blood-thinning medicine during the removal of polyps from the colon or rectum.
It includes patients who regularly take blood thinners and need an elective colonoscopy.
The main goal is to see how often patients have serious bleeding after the polyp removal within 30 days.
The study is being done in several hospitals, and doctors evaluating the results do not know which treatment patients receive.
This multicenter, phase IV, assessor-blinded, non-inferiority clinical trial evaluates the safety of maintaining oral anticoagulant therapy during colorectal polypectomy. The study population includes patients receiving chronic oral anticoagulation treatment with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) who are scheduled for elective colonoscopy for any indication.
The primary objective is to assess the incidence of clinically significant post-polypectomy bleeding within 30 days after the procedure. The trial tests the hypothesis that continuing anticoagulant therapy during polypectomy is non-inferior to interrupting it, with a non-inferiority margin set at 10%.
A total of 481 patients will be enrolled, with 241 patients per group. The intervention consists of maintaining ongoing anticoagulant treatment without modification before the procedure. This trial is classified as a low-intervention study according to regulatory guidelines and aims to provide evidence to optimize the management of anticoagulated patients undergoing colorectal polypectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Age over 85 years.
Urgent colonoscopy.
Labile (time in therapeutic range less than 60%) documented in the previous 3 months in patients receiving VKAs.
Supratherapeutic INR (>3.5) at the time of the procedure in patients on VKAs.
Pregnancy.
Decompensated liver cirrhosis.
Inability, at the investigator's discretion, to understand the periprocedural anticoagulation regimen.
Known coagulopathy or bleeding diathesis, including count \<50,000/µl in the previous 12 months.
Scheduled endoscopic dilation.
Severe psychiatric disorder.
Removal of colorectal lesions by endoscopic submucosal dissection.
Previous diagnosis of renal failure defined as creatinine >2 mg/dl or clearance \<30 ml/min.
Planned high bleeding risk procedure during simultaneous gastroscopy.
Previous inclusion in the trial. Patients may only be included once.
Patients who are not candidates for a second endoscopic intervention due to clinical conditions.
Any clinical situation or concomitant treatment that, in the investigator's opinion, poses a significant bleeding risk.
Patients with polyps larger than 4 cm pending endoscopic resection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this treatment group will continue their anticoagulant therapy during the procedure. For those on vitamin K antagonists (VKAs), INR levels will be checked 7-14 days before the endoscopy, and doses adjusted if necessary to maintain therapeutic range (\<3.5) before the procedure. Patients on direct oral anticoagulants (DOACs) will skip only the morning dose on the day of the procedure without other changes.
Procedure: To maintain anticoagulant therapy during the polypectomy of colorectal lesions
In patients assigned to this treatment arm, anticoagulation will be temporarily discontinued following the recommendations of the 2021 BSG-ESGE clinical practice guideline. The distinction between high and low thrombotic risk will be made according to guidelines.
Group A
Clinically significant intraprocedural bleeding
Major bleeding during colonoscopy that requires procedure interruption, a drop in hemoglobin \>2 g/dL, blood transfusion, interventional radiology, hospitalization, surgery, or results in death. The following data will be collected for bleeding events: * Date of the event. * Length of hospital stay: Quantitative nominal variable. Unit: days. * ICU admission: Binary variable (Yes/No). * Severity: Assessed according to the ASGE classification.
Time frame: 1 month
Clinically significant delayed hemorrhage
Gastrointestinal bleeding occurring within 30 days after completion of the colonoscopy that requires an emergency visit, hospitalization, or an intervention. Date of the event. - Length of hospital stay: Quantitative nominal variable. Unit: days. - ICU admission: Binary variable (Yes/No). - Severity: Assessed according to the ASGE classification.
Time frame: 1 month
Acute Myocardial Infarction
A clinical syndrome characterized by evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Data collected will include event date, hospital stay duration, and ICU stay duration.
Time frame: 1 month
Hospitalization for Unstable Angina
Unscheduled hospitalization for the treatment of unstable angina occurring within 24 hours from symptom onset. Hospitalization is defined as admission to an inpatient unit or an emergency department visit resulting in a stay of at least 24 hours. Data collected will include event date, hospital stay duration, and ICU stay duration.
Time frame: 1 month
Deep Vein Thrombosis
Any deep vein thrombosis diagnosed in the upper body (internal jugular, subclavian, axillary/brachial) or lower extremities (iliac, femoral/popliteal, gastrocnemius, peroneal, posterior tibial), or in the inferior vena cava or deep splanchnic veins, as confirmed by ultrasound or contrast imaging techniques including computed tomography (CT), angiography, or magnetic resonance imaging (MRI). Data collected will include event date, hospital stay duration, and ICU stay duration.
Time frame: 1 month
Pulmonary Embolism
Any pulmonary embolism diagnosed by computed tomography (CT), ventilation-perfusion (V/Q) scan, invasive pulmonary angiography, echocardiography (thrombus visualized in the main pulmonary artery), or confirmed by autopsy. Data collected will include event date, hospital stay duration, and ICU stay duration.
Time frame: 1 month
Stroke, Including Transient Ischemic Attack
Stroke is defined as an acute episode of focal or global neurological dysfunction caused by a cerebral, spinal, or retinal vascular injury as a result of hemorrhage or infarction. Transient ischemic attack (TIA) is defined as a temporary (\< 24 hours) episode of focal neurological dysfunction caused by cerebral, spinal, or retinal ischemia without acute infarction. Data collected will include event date, hospital stay duration, and ICU stay duration.
Time frame: 1 month
Peripheral Arterial Embolism or Thrombosis
Any embolism or arterial thrombosis diagnosed by computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) involving the splanchnic circulation, upper or lower extremities, or renal arteries. Data collected will include event date, type, hospital stay duration, and ICU stay duration.
Time frame: 1 month
Clinically non-significant intraprocedural bleeding
Bleeding that persists for more than 1 minute, requires endoscopic treatment, and does not meet the criteria for clinically significant intraprocedural bleeding.
Time frame: 1 month
Death
It will be recorded as a nominal categorical variable: \- No/death If death is selected: Cause/unknown cause. It will be also recorded the date of death
Time frame: 1 month
Plan to share: No
Started Oct 2024 (actual). Primary completion is estimated for Nov 2026, 25 months after the start.
Of 92 non-industry phase 4 interventional studies under Hemorrhage, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 25 months is below that.
Counting every sponsor, half of 96 studies reached it within 28 months; a quarter within 18 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Outcomes'10